BCZ

3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID


Toggle HydrogenToggle Labels

Chemical Component Summary

Name3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID
SynonymsBCX-1812
Identifiers(1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-carbamimidamido-2-hydroxy-cyclopentane-1-carboxylic acid
FormulaC15 H28 N4 O4
Molecular Weight328.407
TypeNON-POLYMER
Isomeric SMILESCCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)NC(=N)N)NC(=O)C
InChIInChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
InChIKeyXRQDFNLINLXZLB-CKIKVBCHSA-N

Chemical Details

Formal Charge0
Atom Count51
Chiral Atom Count5
Bond Count51
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB06614 
NamePeramivir
Groups
  • approved
  • investigational
DescriptionPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
Synonyms
  • Peramivir
  • Peramivir hydrate
  • Peramivir anhydrous
Brand Names
  • Rapivab
  • Alpivab
IndicationPeramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.[L36768]
Categories
  • Amidines
  • Anti-Infective Agents
  • Antiinfectives for Systemic Use
  • Antiviral Agents
  • Antivirals for Systemic Use
ATC-CodeJ05AH03
CAS number330600-85-6

Drug Targets

NameTarget SequencePharmacological ActionActions
NeuraminidaseMNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEA...unknown
NeuraminidaseMNPNQKIITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECSSPPNNQV...unknown
NeuraminidaseMLPSTIQTLTLFLTSGGVLLSLYVSASLSYLLYSDILLKFSSKITAPTMT...unknown
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 154234, 86310107
ChEMBL CHEMBL139367
ChEBI CHEBI:85202